248 related articles for article (PubMed ID: 24712891)
1. Considerations in individualizing prophylaxis in patients with haemophilia A.
Valentino LA
Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
[TBL] [Abstract][Full Text] [Related]
2. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
3. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
4. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
Schlenkrich S; Schubert C
Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
[TBL] [Abstract][Full Text] [Related]
5. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
[TBL] [Abstract][Full Text] [Related]
6. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
[TBL] [Abstract][Full Text] [Related]
7. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
8. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
9. Rationale for individualizing haemophilia care.
Sørensen B; Auerswald G; Benson G; Elezović I; Felder M; Lambert T; Morfini M; Remor E; Salaj P; Santagostino E; Šalek SZ; Ljung R
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):849-57. PubMed ID: 25396764
[TBL] [Abstract][Full Text] [Related]
10. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis in adults with haemophilia.
Hay CR
Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of individualized primary prophylactic treatment of 19 cases of children with severe hemophilia A].
Liu GQ; Tang L; Wu XY; Zhen YZ; Li G; Chen ZP; Wang Y; Zhang NN; Zhang JS; Yu GX; Wu RH
Zhonghua Er Ke Za Zhi; 2016 Dec; 54(12):923-926. PubMed ID: 27938593
[No Abstract] [Full Text] [Related]
14. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
Walsh CE; Valentino LA
Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
[TBL] [Abstract][Full Text] [Related]
15. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.
Rossbach HC
Vasc Health Risk Manag; 2010 Mar; 6():59-68. PubMed ID: 20234780
[TBL] [Abstract][Full Text] [Related]
16. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
[TBL] [Abstract][Full Text] [Related]
17. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
18. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
[TBL] [Abstract][Full Text] [Related]
19. Methods for individualising factor VIII dosing in prophylaxis.
Ar MC; Vaide I; Berntorp E; Björkman S
Eur J Haematol Suppl; 2014 Aug; 76():16-20. PubMed ID: 24957103
[TBL] [Abstract][Full Text] [Related]
20. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
